Shares of Renalytix Plc (LON:RENX – Get Free Report) traded up 2.5% on Wednesday . The company traded as high as GBX 1.85 and last traded at GBX 1.85. 172,529 shares traded hands during mid-day trading, a decline of 82% from the average session volume of 958,257 shares. The stock had previously closed at GBX 1.80.
Renalytix Trading Up 11.1%
The stock has a market capitalization of £8.74 million, a P/E ratio of -0.50 and a beta of 1.97. The stock has a 50-day moving average price of GBX 2.13 and a two-hundred day moving average price of GBX 4.54. The company has a debt-to-equity ratio of -118.57, a quick ratio of 2.42 and a current ratio of 1.21.
Renalytix Company Profile
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
Featured Stories
- Five stocks we like better than Renalytix
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
